Press Releases Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Investor Overview News Press Releases Media Events and Presentations EVENTS AND PRESENTATIONS SCIENTIFIC PUBLICATIONS AND PRESENTATIONS Analyst Coverage SEC Filings Stock Information Stock Quote & Chart Historical Price Lookup Investment Calculator Corporate Governance Governance Overview Management Board of Directors Committee Composition Information Request Year None2026202520242023202220212020 August 11, 2026 Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update May 20, 2026 Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA May 18, 2026 Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 May 15, 2026 Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC May 13, 2026 Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update April 27, 2026 Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting March 10, 2026 Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update February 23, 2026 TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer February 19, 2026 Protara Therapeutics to Participate in Upcoming Investor Conferences February 2, 2026 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 22, 2026 Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium January 12, 2026 Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 12 of 138 Print Print Email Alerts Email Alerts RSS Feeds RSS Feeds Email Page Email Page
Year None2026202520242023202220212020 August 11, 2026 Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update May 20, 2026 Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA May 18, 2026 Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026 May 15, 2026 Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC May 13, 2026 Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update April 27, 2026 Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting March 10, 2026 Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update February 23, 2026 TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer February 19, 2026 Protara Therapeutics to Participate in Upcoming Investor Conferences February 2, 2026 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 22, 2026 Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium January 12, 2026 Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page › Last page » Displaying 1 - 12 of 138
August 11, 2026 Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
May 20, 2026 Protara Therapeutics to Present at the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
May 18, 2026 Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
May 15, 2026 Protara Therapeutics Announces Positive Updated 12-Month Data Demonstrating Durable Responses in the Fully Enrolled BCG-Naïve Cohort of the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 in NMIBC
May 13, 2026 Protara Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
April 27, 2026 Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
March 10, 2026 Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
February 23, 2026 TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
February 2, 2026 Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 22, 2026 Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
